Emkay's research report on Dalmia Bharat
We downgrade Dalmia Bharat to REDUCE from Buy owing to limited growth catalysts due to i) uncertainty over the Jaypee deal—as admitted to the NCLT by lenders—impacting the company’s market diversification and delaying its plans of becoming a pan-India player; ii) no major announcement on near-term organic plans; and iii) limited levers for cost improvement, in our view. We exclude acquisition of JP assets from our estimates, implying lower volume growth. Prices in its key markets like the South and East are likely to remain volatile owing to capacity additions. Accordingly, we now build-in ~8% volume CAGR with EBITDA/t in the Rs900-1,000 range over FY24-27E. Also, factoringin lower cement prices,
Outlook
We cut our EBITDA estimates by 7-16% for FY25-26. Stripping out the JP assets, we see limited potential for any stock re-rating for Dalmia. Accordingly, we cut our target EV/E to 11x (vs 12.5x earlier) and revise down our Jun-25E TP to Rs1,800/share, post quarterly roll-over.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.